Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Warren

Showing results (111-120 of 257) with videos related to

Pageof 26
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|June 18, 2026
Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic reviewFatimah Khoda, Yasmin Khan, William W Y Haw, et al.
Dermatology and Therapy|October 8, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsBruce Strober, Wolf-Henning Boehncke, James G Krueger, et al.
Lancet (London, England)|December 26, 2016
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialRichard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, et al.
The Journal of Investigative Dermatology|February 8, 2008
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasisRichard B Warren, Rhodri L L Smith, Emanuela Campalani, et al.
Clinical and Experimental Dermatology|October 19, 2024
Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Kerry Williams, Georgia Lada, Nick J Reynolds, et al.
Cells|September 8, 2023
Human Mast Cells Upregulate Cathepsin B, a Novel Marker of Itch in PsoriasisPeter W West, Chiara Tontini, Haris Atmoko, et al.
The Journal of Investigative Dermatology|November 13, 2013
Polymorphisms in IL-1B distinguish between psoriasis of early and late onsetHarry L Hébert, John Bowes, Rhodri L Smith, et al.
The British Journal of Dermatology|December 5, 2023
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.
JAMA Dermatology|December 2, 2020
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators RegisterZenas Z N Yiu, Kayleigh J Mason, Philip J Hampton, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 8, 2022
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tabletsRichard B Warren, Bruce Strober, Jonathan I Silverberg, et al.
Pageof 26

Showing results (111-120 of 257) with videos related to

Sort By:
Pageof 26
Journal of the European Academy of Dermatology and Venereology : JEADV|June 18, 2026
Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic reviewFatimah Khoda, Yasmin Khan, William W Y Haw, et al.
Dermatology and Therapy|October 8, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical TrialsBruce Strober, Wolf-Henning Boehncke, James G Krueger, et al.
Lancet (London, England)|December 26, 2016
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialRichard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, et al.
The Journal of Investigative Dermatology|February 8, 2008
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasisRichard B Warren, Rhodri L L Smith, Emanuela Campalani, et al.
Clinical and Experimental Dermatology|October 19, 2024
Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Kerry Williams, Georgia Lada, Nick J Reynolds, et al.
Cells|September 8, 2023
Human Mast Cells Upregulate Cathepsin B, a Novel Marker of Itch in PsoriasisPeter W West, Chiara Tontini, Haris Atmoko, et al.
The Journal of Investigative Dermatology|November 13, 2013
Polymorphisms in IL-1B distinguish between psoriasis of early and late onsetHarry L Hébert, John Bowes, Rhodri L Smith, et al.
The British Journal of Dermatology|December 5, 2023
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.
JAMA Dermatology|December 2, 2020
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators RegisterZenas Z N Yiu, Kayleigh J Mason, Philip J Hampton, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 8, 2022
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tabletsRichard B Warren, Bruce Strober, Jonathan I Silverberg, et al.
Pageof 26